Psa: past, today and tomorrow

Levent Mert Gunay; Sertac Yazici; Haluk Ozen

Psa: past, today and tomorrow

Levent Mert Gunay
, Sertac Yazici
, Haluk Ozen

Near East University
Cerrahpaşa Tip Fak.
Hacettepe University

Research output: Contribution to journal › Review article › peer-review

Abstract

Aim: To review the evolution and use of prostate specific antigen (PSA) in clincal aplications in a brief report with historical perspective.Results: For more than a decade PSA is used as a reliable biomarker for screning and post-treatment follow up of prostate cancer. The PSA thresholds are continually refined and altered in years. The use of PSA isoforms and PSA kinetics increased the strength of PSA in diagnosis and follow-up of cancer.Conclusion: PSA is a reliable biomaker for follow-up after prostate cancer. Its diagnostic strength needs to be supported with several other parameters. The search for new biological markers that can complement PSA still continues.

Original language	Turkish
Pages (from-to)	5-10
Number of pages	6
Journal	Uroonkoloji Bulteni-bulletin of Urooncology
Volume	10
Issue number	2
Publication status	Published - Jun 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{6cc57e4d902c4bd8aa4ae7e474fae837,

title = "Psa: past, today and tomorrow",

abstract = "Aim: To review the evolution and use of prostate specific antigen (PSA) in clincal aplications in a brief report with historical perspective.Results: For more than a decade PSA is used as a reliable biomarker for screning and post-treatment follow up of prostate cancer. The PSA thresholds are continually refined and altered in years. The use of PSA isoforms and PSA kinetics increased the strength of PSA in diagnosis and follow-up of cancer.Conclusion: PSA is a reliable biomaker for follow-up after prostate cancer. Its diagnostic strength needs to be supported with several other parameters. The search for new biological markers that can complement PSA still continues.",

keywords = "Early diagnosis, Prostate cancer, Prostate specific antigen, Screening",

author = "Gunay, \{Levent Mert\} and Sertac Yazici and Haluk Ozen",

year = "2011",

month = jun,

language = "T{\"u}rk{\c c}e",

volume = "10",

pages = "5--10",

journal = "Uroonkoloji Bulteni-bulletin of Urooncology",

issn = "2147-2270",

publisher = "Galenos Yayincilik",

number = "2",

}

TY - JOUR

T1 - Psa

T2 - past, today and tomorrow

AU - Gunay, Levent Mert

AU - Yazici, Sertac

AU - Ozen, Haluk

PY - 2011/6

Y1 - 2011/6

N2 - Aim: To review the evolution and use of prostate specific antigen (PSA) in clincal aplications in a brief report with historical perspective.Results: For more than a decade PSA is used as a reliable biomarker for screning and post-treatment follow up of prostate cancer. The PSA thresholds are continually refined and altered in years. The use of PSA isoforms and PSA kinetics increased the strength of PSA in diagnosis and follow-up of cancer.Conclusion: PSA is a reliable biomaker for follow-up after prostate cancer. Its diagnostic strength needs to be supported with several other parameters. The search for new biological markers that can complement PSA still continues.

AB - Aim: To review the evolution and use of prostate specific antigen (PSA) in clincal aplications in a brief report with historical perspective.Results: For more than a decade PSA is used as a reliable biomarker for screning and post-treatment follow up of prostate cancer. The PSA thresholds are continually refined and altered in years. The use of PSA isoforms and PSA kinetics increased the strength of PSA in diagnosis and follow-up of cancer.Conclusion: PSA is a reliable biomaker for follow-up after prostate cancer. Its diagnostic strength needs to be supported with several other parameters. The search for new biological markers that can complement PSA still continues.

KW - Early diagnosis

KW - Prostate cancer

KW - Prostate specific antigen

KW - Screening

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000219390000002&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - İnceleme makalesi

SN - 2147-2270

VL - 10

SP - 5

EP - 10

JO - Uroonkoloji Bulteni-bulletin of Urooncology

JF - Uroonkoloji Bulteni-bulletin of Urooncology

IS - 2

ER -

Psa: past, today and tomorrow

Abstract

UN SDGs

Other files and links

Cite this